Colorectal Cancer Screening Market Size & Outlook, 2026-2034

Colorectal Cancer Screening Market Overview

The global colorectal cancer screening market size is valued at USD 16.1 billion in 2025 and is estimated to reach USD 36 billion by 2034, growing at a CAGR of 8% during the forecast period. This growth can be attributed to the rising incidence of colorectal cancer and increasing financial burden on healthcare, growing demand for colorectal cancer testing, advances in genomics and molecular diagnostics, and promoting early cancer detection to enable reduced treatment costs. 

Key Market Trends and Insights

• North America dominated the market, accounting for the largest revenue share of 42% in 2025.
• The Asia Pacific region is expected to witness the fastest growth in the market, with a CAGR of 9.2% during the forecast period.
• By Screening Test, the colonoscopy segment is the highest contributor with a market share of 48%.
• By End-User, Diagnostic Imaging Centers are the fastest-growing segment in the market and are expected to grow at a CAGR of 7.80% throughout the forecast period.
• The U.S. is the dominating country in the colorectal cancer screening market.

Market Size & Forecast

• 2025 Market Size: USD 16.1 billion
• 2034 Projected Market Size: USD 36 billion
• CAGR (2026-2034): 8%
• Dominating Region: North America
• Fastest-Growing Region: Asia Pacific

Colorectal Cancer (CRC) occurs when cancerous cells begin to grow and spread in the colon or rectum, part of the digestive tract. Colorectal cancer screening helps detect the cancer in asymptomatic and high-risk patients aged 45 and above. The rising incidence rates of colorectal cancer, particularly among individuals aged 50 and above, are propelling the demand for early and accurate screening methods. Furthermore, the growing emphasis on preventive healthcare is likely to encourage more individuals to participate in screening programs, thereby potentially reducing the incidence and mortality associated with this disease.

Latest Market Trends

Shift toward Non-Invasive Screening

The colorectal cancer screening market is increasingly shifting toward non-invasive screening methods to improve participation and accessibility. Non-invasive options such as faecal immunochemical tests (FIT), stool DNA tests, and emerging blood-based assays offer convenience, at-home usage, and greater patient acceptance. Technological advancements in biomarker detection have improved test accuracy, supporting their adoption as first-line screening tools, particularly in large-scale population screening programs and regions with limited endoscopy capacity.

Expanding Awareness and Educational Programs

Expanding awareness and educational programs are emerging as a significant trend in the market, driven by increasing efforts from governments, healthcare organisations, and non-profits to promote early detection. Public health campaigns, workplace wellness initiatives, and community outreach programs are helping to improve understanding of colorectal cancer risks and the benefits of routine screening. Educational initiatives also focus on reducing stigma and fear associated with screening procedures, particularly colonoscopy, while highlighting non-invasive options.

To get more insights about this report Download Free Sample Report

Market Drivers

Lifestyle and Environmental Risk Factors

Lifestyle and environmental risk factors are significant drivers of colorectal cancer incidence, thereby increasing demand for screening. Diets high in red and processed meats, low fibre intake, and excessive consumption of alcohol contribute to higher cancer risk. Sedentary lifestyles, obesity, and smoking further elevate susceptibility. Environmental factors, including exposure to air pollution, industrial chemicals, and certain occupational hazards, also play a role. These combined lifestyle and environmental influences have led to a rising prevalence of colorectal cancer globally, prompting governments, healthcare providers, and individuals to prioritise early detection through regular screening, driving sustained growth in the market.

Market Restraints

Limitations in the Accuracy and Reliability of Certain Tests

Sampling errors can impact the accuracy of certain colorectal cancer diagnostic tests, particularly those that involve tissue or stool specimens. The reliability of test results may be compromised by improper sample collection, handling, or processing. Additionally, colorectal cancer exhibits significant heterogeneity due to diverse genetic mutations and molecular subtypes. This biological variability can influence the performance of diagnostic tests designed to detect specific biomarkers or molecular signatures, potentially leading to inconsistent outcomes.

Market Opportunity

Innovations in Imaging Technologies

Advanced imaging technologies such as CT, MRI, and PET scans produce high-resolution images of the colon and rectum, enabling clinicians to detect abnormalities like polyps or tumours at an early stage. Early detection is critical for timely intervention and improving treatment outcomes in colorectal cancer management. Integrating artificial intelligence (AI) and machine learning with these imaging modalities offers significant potential to enhance diagnostic accuracy. AI-assisted image analysis supports radiologists in interpreting complex imaging data more efficiently and precisely, facilitating faster diagnosis, personalised treatment planning, and improved clinical decision-making for patients with colorectal cancer.

Regional Analysis

According to Straits Research, North America dominated the market with the largest revenue share of 42% in 2025. This region is the biggest revenue generator in the market, due to the high incidence rates of colorectal cancer in the area. Cases are especially very high in the United States, where colorectal cancer is the third most common cancer. Advanced healthcare infrastructure, robust government initiatives for screening, and the widespread adoption of innovative screening technologies, such as genetic tests and AI-assisted tools, have supported North America's strong market position.

The U.S. Market: The United States is the leading country in the North American market due to its high colorectal cancer prevalence, advanced healthcare infrastructure, widespread adoption of screening technologies, strong government and insurance support for preventive care, and high public awareness of early detection benefits. The U.S. also experiences significant market activity from key players, extensive use of colonoscopies and non-invasive tests, such as FIT and stool DNA tests, and a growing adoption of AI-assisted diagnostic tools, all of which reinforce its dominant position in the region.

Asia Pacific Market Insights

The Asia Pacific is the fastest-growing region, with a CAGR of 9.2% during the forecast period for colorectal cancer screening, driven by the rapidly increasing prevalence of this condition in countries such as China, Japan, and India. The demographic impact of an ageing population, along with the introduction of national screening programs, is making way for screening services. Improvements in healthcare infrastructure, along with the expansion of sophisticated diagnostic tools in these countries, are supporting rapid market growth.

China leads the Asia Pacific colorectal cancer screening market due to its large population, rising colorectal cancer incidence, and expanding government-led screening programs. Increasing urbanisation, changing lifestyles, and growing awareness of preventive healthcare are driving higher demand for both invasive and non-invasive screening methods. The country’s healthcare infrastructure is rapidly improving, enabling wider access to advanced diagnostic tools, including colonoscopies, FIT tests, and stool DNA tests.

Europe Market Insights

Europe’s colorectal cancer screening market is growing, driven by government initiatives and public awareness campaigns promoting early detection and prevention to reduce mortality. Rising demand for advanced screening technologies, including genetic tests and non-invasive methods, is supported by favourable reimbursement policies. Key markets in the region include Germany, France, and the UK, where healthcare systems are actively adopting innovative screening solutions. These factors collectively contribute to Europe’s expanding market and the broader emphasis on timely diagnosis and preventive care.

Germany dominates Europe’s market, supported by comprehensive national screening programs, high colonoscopy rates, and the widespread adoption of both invasive and non-invasive screening methods. Additionally, strong healthcare systems, public awareness initiatives, and government-led programs are driving the uptake of screening.

Latin America Market Insights

Latin America’s colorectal cancer screening market is growing steadily, supported by rising awareness, increasing healthcare investment, and a growing burden of colorectal cancer in key countries such as Brazil and Mexico. Non-invasive and minimally invasive screening methods, such as faecal immunochemical tests (FIT) and DNA-based stool tests, are driving demand across the region. LATAM exhibits significant growth potential, despite challenges in healthcare access and economic disparities, which reflects an expanding market for colorectal cancer screening services and technologies.

Brazil leads the Latin American market, owing to its large population, well-developed healthcare infrastructure, and government-supported early detection programs. Mexico and other countries are also contributing to regional growth through rising awareness and increased screening initiatives. Brazil’s dominance stems from its extensive healthcare coverage and established screening efforts, reflecting Latin America’s overall shift toward organised colorectal cancer screening and the growing use of both non-invasive and conventional diagnostic methods across the region.

Middle East and Africa Market Insights

The Middle East and Africa market is witnessing steady growth driven by increasing awareness and government initiatives aimed at early detection. The region is witnessing a gradual shift towards preventive healthcare, with various countries implementing screening programs to address the rising incidence of colorectal cancer. Regulatory support and public health campaigns are crucial in raising awareness of screening among the population. The focus on improving healthcare access and education is expected to drive growth, positioning the Middle East and Africa as an emerging market for colorectal cancer screening solutions.

Saudi Arabia is the leading country in the MEA colorectal cancer screening market, driven by its robust healthcare infrastructure, government-supported screening initiatives, and increasing public awareness of colorectal cancer. Saudi Arabia’s leadership reflects the MEA market’s emphasis on increasing access to screening, utilising both invasive and non-invasive diagnostic methods, and focusing on early detection to improve patient outcomes and reduce colorectal cancer-related mortality in the region.

Screening Test Insights

According to Straits Research, the colonoscopy segment leads the colorectal cancer screening market, holding a 48% market share, as it effectively detects precancerous lesions and early-stage cancers. By directly visualising the colon, clinicians can remove polyps during the procedure, thereby reducing the risk of cancer. Colonoscopy remains the dominant method due to its comprehensive diagnostic capabilities and established role in routine screening guidelines, especially in developed regions.

The stool-based segment experienced the fastest growth at a CAGR of 11.4%. The Faecal Immunochemical Test (FIT) leads this expansion due to its non-invasive nature, affordability, and ease of use, making it ideal for widespread screening. FIT detects blood in the stool with high specificity, driving adoption, while more advanced stool DNA tests are gaining attention for identifying genetic mutations linked to colorectal cancer. The segment’s growth is fueled by patient preference for non-invasive methods, home-based sample collection, and healthcare initiatives promoting early detection across diverse populations, increasing overall demand for stool-based screening.

End-User Insights

The Hospitals and Clinics segment leads the colorectal cancer screening market with a 58% share, primarily due to their comprehensive diagnostic services, advanced equipment such as colonoscopes, and skilled staff capable of performing polypectomy and biopsy procedures. These facilities perform a significant proportion of colonoscopies, making them the gold standard for colon cancer screenings. National guidelines also recommend regular screenings in hospitals and clinics, emphasising their crucial role in early cancer detection and timely intervention, which drives their market dominance.

Diagnostic Imaging Centers are the fastest-growing segment in the market and are expected to grow at a CAGR of 7.80% throughout the forecast period. The growth of diagnostic imaging centres is driven by the rising adoption of non-invasive techniques, such as CT colonography, which offer greater patient comfort and lower risk than traditional colonoscopies. Advanced imaging provides more accurate diagnostic results, encouraging centres to expand services to meet the increasing demand from patients who prefer less invasive options.

Competitive Landscape

The colorectal cancer screening market is moderately fragmented, characterised by the presence of global diagnostics leaders alongside emerging biotechnology firms focused on molecular and non-invasive screening solutions. Market competition is shaped by technological innovation, expanding screening programs, growing awareness of early cancer detection, and increasing preference for non-invasive and at-home testing modalities. While several companies compete across stool-based tests, blood-based biomarkers, imaging technologies, and endoscopic solutions, established players continue to hold significant influence due to their strong distribution networks, regulatory approvals, and extensive clinical validation.

Abbott Laboratories- A Market Leader

Abbott Laboratories is a leading multinational healthcare company with a strong presence across diagnostics, medical devices, pharmaceuticals, and nutrition products. Within the market, Abbott benefits from its robust diagnostics portfolio, large-scale commercialisation capabilities, and strong relationships with healthcare providers, laboratories, and retail channels. Abbott’s strategic focus on rapid, decentralised, and accessible diagnostic testing positions it favorably in colorectal cancer screening, particularly as healthcare systems emphasise early detection and population-level screening.

Latest News 

• In November 2025, Abbott Laboratories announced a landmark acquisition of Exact Sciences for approximately USD 23 billion, marking its largest acquisition in nearly a decade. This deal significantly strengthened Abbott’s position in cancer diagnostics by adding Cologuard, a leading non-invasive stool-based colorectal cancer screening test that is widely adopted in the U.S. market.

List of key players in Colorectal Cancer Screening Market

1. Exact Sciences Corp.
2. Danaher Corp.
3. Diacarta
4. Eiken Chemical Co., Ltd.
5. Freenome Holdings Inc.
6. Fujifilm Holdings Corp.
7. GI-View
8. Guardant Health
9. Hangzhou Novahealth Technology Co, Ltd.
10. Laboratory Corporation of America Holdings
11. Lepu Medical Technology (Beijing) Co., Ltd.
12. Mainz Biomed N.V.
13. Novigenix SA
14. Olympus Corp.
15. Quest Diagnostics Inc.
16. QuidelOrtho Corp.

To get more findings about this report Download Market Share

Strategic Initiatives

• September 2025 - Healthmine, a leading member engagement and rewards platform for health plans, announced a strategic partnership with Exact Sciences, a global leader in cancer diagnostics, to improve colorectal cancer screening completion rates.
• December 2025 - Paradigm Health has announced a partnership with Rocheas part of its effort to utilise artificial intelligence (AI) to enhance patient enrollment in clinical trials.